株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国の体外診断 (IVD) 産業:2019-2025年

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

発行 ResearchInChina 商品コード 877638
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.36円で換算しております。
Back to Top
中国の体外診断 (IVD) 産業:2019-2025年 China In Vitro Diagnostic (IVD) Industry Report, 2019-2025
出版日: 2019年06月29日 ページ情報: 英文 150 Pages
概要

中国の体外診断 (IVD) の市場は数年に及ぶ需要拡大により急成長を遂げており、2018年の市場規模は年率19.3%増の576億人民元と推計されています。

当レポートでは、中国の体外診断 (IVD) 産業を調査し、産業の発展の推移、市場構造および競合パターン、市場規模の推移・予測、診断区分・下流部門別の詳細分析、主要な外資企業・国内企業のプロファイルなどをまとめています。

第1章 概要

  • 定義
  • 分類

第2章 中国の体外診断 (IVD) 産業

  • 発展状況
  • 市場規模
  • 市場構造
  • 競合パターン
  • 発展動向
    • 人口の高齢化
    • 医療関連支出の増加
    • 政府による産業支援
    • ハイエンド免疫学的診断・分子診断・POCT
    • 関連企業の資本市場への集中
    • 「二人っ子政策」
    • 多数のM&Aによる市場の集中

第3章 中国のIVD市場:診断区分別

  • コンパニオン診断
    • 発展状況
    • 市場構造
    • 市場規模
    • 成長推進因子
    • 競合パターン
  • 免疫診断
    • 発展状況
    • 競合パターン
    • 発展動向
  • 分子診断
    • 発展状況
    • 競合パターン
    • 発展動向
  • 生化学的診断
    • 発展状況
    • 競合パターン
    • 発展動向
  • POCT
    • 発展状況
    • 競合パターン
    • 発展動向

第4章 中国のIVD市場:下流部門別

  • 医療制度
    • 医療機関数
    • 医療サービス
    • 医業収入
  • 独立系臨床ラボ
    • 発展状況
    • 市場規模
    • 競合パターン
    • 発展動向

第5章 主要外資企業

  • Roche
  • Siemens
  • Abbott
  • Thermo Fisher
  • Danaher
  • Sysmex

第6章 主要国内企業

  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Autobio Diagnostics Co., Ltd.
  • Beijing Strong Biotechnologies, Inc.
  • MedicalSystem Biotechnologies Co., Ltd.
  • DAAN Gene Co., Ltd. of Sun Yat-sen University
  • Beijing Leadman Biochemistry Co., Ltd.
  • Sinocare Inc.
  • Shanghai Kehua Bio-Engineering Co., Ltd.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Maccura Biotechnologies Co., Ltd.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Biosino Bio-Technology and Science Inc.
  • Jiangsu Bioperfectus Technologies Co., Ltd.
  • Zhejiang Orient Gene Biotech Co., Ltd.
  • HOB Biotech Group Suzhou Co., Ltd.
  • Lifotronic Technology Co., Ltd.
  • Hotgen Biotech Co., Ltd.
  • Dirui Industrial Co., Ltd.
  • Getein Biotech, Inc.
  • Guangdong Hybribio Biotech Co., Ltd.
  • Beijing Bohui Innovation Biotechnologies Co., Ltd.
  • Edan Instruments, Inc.
  • Wuhan Easy Diagnosis Biomedicine Co., Ltd.
図表

Selected Charts

  • Classification of In Vitro Diagnosis
  • Classification of In Vitro Diagnostic Instruments
  • Classification of In Vitro Diagnostic Reagents
  • Global In Vitro Diagnostic Market Size, 2015-2018
  • Medical Instrument Market Size in China, 2013-2018
  • Development History of In Vitro Diagnostic Industry in China
  • In Vitro Diagnostic Market Size in China, 2009-2018
  • In Vitro Diagnostic Market Size in China, 2018-2025E
  • In Vitro Diagnostic Market Structure in China (by Type), 2018
  • In Vitro Diagnostic Market Structure in China (by Product), 2018
  • Competition Pattern of Diagnostic Reagent Industry in China
  • In Vitro Diagnostic Product Layout of Chinese In Vitro Diagnostic Companies
  • IVD Revenue of Major Diagnostic Reagent Enterprises in China, 2014-2018
  • IVD Market Share of Major Diagnostic Reagent Enterprises in China, 2014-2018
  • Population Aged over 60 in China, 2009-2018
  • Total Health Expenditure in China, 2010-2018
  • Policies on In Vitro Diagnostic Industry in China, 2012-2018
  • Development Prospects of In Vitro Diagnostic Market Segments in China
  • Development History of Companion Diagnostic Reagent Kits
  • Joint Launch History of Targeted Drugs and their Companion Diagnostic
  • Companion Diagnostic Reagents Approved by FDA for Marketing
  • Number of Companion Diagnostic Products Approved in the US (by Technology)
  • Market Share of Companion Diagnostic Reagents in the US (by Technology), 2018
  • Number of Companion Diagnostic Products Approved in the US (by Target)
  • Number of Companion Diagnostic Products Approved in the US (by Indication)
  • Market Share of Companion Diagnostic Reagents in the US (by Indication), 2018
  • Global Companion Diagnostic Market Size, 2016-2025E
  • Companion Diagnostic Market Size in China, 2016-2025E
  • FDA's Regulatory History of Companion Diagnostic Reagents
  • Companion Diagnostic Coverage of Major Insurance Companies in the US
  • Merits and Demerits of Different Companion Diagnostic Business Models
  • Comparison between Five Immunodiagnostic Technologies
  • Chemiluminescence Diagnostic Market Share in China, 2018
  • Chemiluminescence Diagnosis VS Enzyme-linked Immunodiagnosis
  • Comparison between Main Technologies Applied to Molecular Diagnostics
  • Market Share of Molecular Diagnostic Enterprises in China, 2018
  • NGS-based Tumor Diagnostic Reagent Kits of Local Chinese Enterprises in Special Approval Procedures for Innovative Medical Instruments
  • Financing Cases in China's Gene Sequencing Industry, 2017-2018
  • Categories of Biochemical Diagnostic Reagents
  • Categories of Biochemical Diagnostic Systems in China
  • Market Share of Biochemical Diagnostic Enterprises in China, 2018
  • Applied Scenarios and Fields of POCT Products
  • Comparison between POCT and Clinical Laboratory Diagnosis
  • Market Share of POCT Enterprises in China, 2018
  • Layout of Chinese Enterprises in POCT
  • Potential POCT Market Size in China
  • Number of Medical and Health Institutions in China, 2015-2019
  • Number of Hospitals in China, 2009-2019
  • Number of Hospitals in China by Economic Type, 2009-2019
  • Clinic Visits of Medical Institutions in China, 2015-2019
  • Clinic Visits of Hospitals in China, 2009-2019
  • Clinic Visits of Hospitals in China by Economic Type, 2012-2019
  • Total Revenue of Medical and Health Institutions in China, 2010-2018
  • Total Revenue of Medical and Health Institutions in China, 2018-2025E
  • Total Revenue of Hospitals in China, 2009-2018
  • Comparison of Independent Clinical Laboratory Market Penetration between China, Europe, America and Japan, 2018
  • Comparison of Diagnostic Item Quantity among Various Medical Institutions
  • Independent Clinical Laboratory Market Size in China, 2010-2018
  • Number of Independent Clinical Laboratories in China, 2007-2018
  • Independent Clinical Laboratory Revenue of Main Independent Clinical Laboratory Enterprises in China, 2014-2018
  • Marker Share of Independent Clinical Laboratory Enterprises in China, 2018
  • Comprehensive Comparison between Leading Independent Clinical Laboratory Enterprises in China, 2018
  • Independent Clinical Laboratory Market Size and YoY Growth in China, 2018-2025E
  • Policies on Public Hospital Reform in China, 2015-2019
  • Number of Private Hospitals and YoY Growth in China, 2009-2018
  • Clinic Visits of Private Hospitals in China, 2012-2018
  • Population Aged over 60 in China, 2009-2018
  • Market Share of Kingmed Diagnostics, 2014-2018
  • Revenue and Net Income of Roche, 2013-2018
  • Revenue Structure of Roche by Product, 2013-2018
  • IVD Revenue of Roche, 2013-2018
  • Revenue and Net Income of Siemens, 2013-2018
  • Revenue Structure of Siemens by Product, 2013-2018
  • IVD Revenue of Siemens, 2013-2018
  • Revenue and Net Income of Abbott, 2013-2018
  • Revenue Structure of Abbott by Product, 2013-2018
  • IVD Revenue of Abbott, 2013-2018
  • Revenue and Net Income of Thermo Fisher, 2013-2018
  • Revenue Structure of Thermo Fisher by Product, 2013-2018
  • IVD Revenue of Thermo Fisher, 2013-2018
  • Revenue and Net Income of Danaher, 2013-2018
  • Revenue Structure of Danaher by Product, 2013-2018
  • IVD Revenue of Danaher, 2013-2018
  • Revenue and Net Income of Sysmex, 2013-2018
  • Revenue Structure of Sysmex by Product, 2013-2018
  • IVD Revenue of Sysmex, 2013-2018
  • Revenue and Net Income of Shenzhen Mindray Bio-Medical Electronics, 2013-2018
  • Revenue Structure of Shenzhen Mindray Bio-Medical Electronics by Product, 2013-2018
  • Gross Margin of Shenzhen Mindray Bio-Medical Electronics, 2013-2018
  • IVD Revenue of Shenzhen Mindray Bio-Medical Electronics, 2013-2018
  • Revenue and Net Income of Autobio Diagnostics, 2013-2018
  • Revenue Structure of Autobio Diagnostics by Product, 2013-2018
  • Gross Margin of Autobio Diagnostics, 2013-2018
  • IVD Revenue of Autobio Diagnostics, 2013-2018
  • Revenue and Net Income of Beijing Strong Biotechnologies, 2013-2018
  • Revenue Structure of Beijing Strong Biotechnologies by Product, 2013-2018
  • Gross Margin of Beijing Strong Biotechnologies, 2013-2018
  • IVD Revenue of Beijing Strong Biotechnologies, 2013-2018
  • Revenue and Net Income of MedicalSystem Biotechnology, 2013-2018
  • Revenue Structure of MedicalSystem Biotechnology by Product, 2013-2018
  • Gross Margin of MedicalSystem Biotechnology, 2013-2018
  • IVD Revenue of MedicalSystem Biotechnology, 2013-2018
  • Revenue and Net Income of DAAN Gene, 2013-2018
  • Revenue Structure of DAAN Gene by Product, 2013-2018
  • Gross Margin of DAAN Gene, 2013-2018
  • IVD Revenue of DAAN Gene, 2013-2018
  • Revenue and Net Income of Beijing Leadman Biochemistry, 2013-2018
  • Revenue Structure of Beijing Leadman Biochemistry by Product, 2013-2018
  • Gross Margin of Beijing Leadman Biochemistry, 2013-2018
  • IVD Revenue of Beijing Leadman Biochemistry, 2013-2018
  • Revenue and Net Income of Sinocare, 2013-2018
  • Revenue Structure of Sinocare by Product, 2013-2018
  • Gross Margin of Sinocare, 2013-2018
  • IVD Revenue of Sinocare, 2013-2018
  • Revenue and Net Income of Shanghai Kehua Bio-Engineering, 2013-2018
  • Revenue Structure of Shanghai Kehua Bio-Engineering by Product, 2013-2018
  • Gross Margin of Shanghai Kehua Bio-Engineering, 2013-2018
  • IVD Revenue of Shanghai Kehua Bio-Engineering, 2013-2018
  • Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2013-2018
  • Revenue Structure of Shanghai Fosun Pharmaceutical by Product, 2013-2018
  • Gross Margin of Shanghai Fosun Pharmaceutical, 2013-2018
  • IVD Revenue of Shanghai Fosun Pharmaceutical, 2013-2018
  • Revenue and Net Income of Livzon Pharmaceutical Group, 2013-2018
  • Revenue Structure of Livzon Pharmaceutical Group by Product, 2013-2018
  • Gross Margin of Livzon Pharmaceutical Group, 2013-2018
  • IVD Revenue of Livzon Pharmaceutical Group, 2013-2018
  • Revenue and Net Income of Maccura Biotechnology, 2013-2018
  • Revenue Structure of Maccura Biotechnology by Product, 2013-2018
  • Gross Margin of Maccura Biotechnology, 2013-2018
  • IVD Revenue of Maccura Biotechnology, 2013-2018
  • Revenue and Net Income of Guangzhou Wondfo Biotech, 2013-2018
  • Revenue Structure of Guangzhou Wondfo Biotech by Product, 2013-2018
  • Gross Margin of Guangzhou Wondfo Biotech, 2013-2018
  • IVD Revenue of Guangzhou Wondfo Biotech, 2013-2018
  • Revenue and Net Income of Biosino Bio-Technology and Science, 2013-2018
  • Revenue Structure of Biosino Bio-Technology and Science by Product, 2013-2018
  • Gross Margin of Biosino Bio-Technology and Science, 2013-2018
  • IVD Revenue of Biosino Bio-Technology and Science, 2013-2018
  • Revenue and Net Income of Jiangsu Bioperfectus Technologies, 2013-2018
  • Revenue Structure of Jiangsu Bioperfectus Technologies by Product, 2013-2018
  • Gross Margin of Jiangsu Bioperfectus Technologies, 2013-2018
  • IVD Revenue of Jiangsu Bioperfectus Technologies, 2013-2018
  • Revenue and Net Income of Zhejiang Orient Gene Biotech, 2013-2018
  • Revenue Structure of Zhejiang Orient Gene Biotech by Product, 2013-2018
  • Gross Margin of Zhejiang Orient Gene Biotech, 2013-2018
  • IVD Revenue of Zhejiang Orient Gene Biotech, 2013-2018
  • Revenue and Net Income of HOB Biotech Group Suzhou, 2013-2018
  • Revenue Structure of HOB Biotech Group Suzhou by Product, 2013-2018
  • Gross Margin of HOB Biotech Group Suzhou, 2013-2018
  • IVD Revenue of HOB Biotech Group Suzhou, 2013-2018
  • Revenue and Net Income of Lifotronic Technology, 2013-2018
  • Revenue Structure of Lifotronic Technology by Product, 2013-2018
  • Gross Margin of Lifotronic Technology, 2013-2018
  • IVD Revenue of Lifotronic Technology, 2013-2018
  • Revenue and Net Income of Hotgen Biotech, 2013-2018
  • Revenue Structure of Hotgen Biotech by Product, 2013-2018
  • Gross Margin of Hotgen Biotech, 2013-2018
  • IVD Revenue of Hotgen Biotech, 2013-2018
  • Revenue and Net Income of Dirui Industrial, 2013-2018
  • Revenue Structure of Dirui Industrial by Product, 2013-2018
  • Gross Margin of Dirui Industrial, 2013-2018
  • IVD Revenue of Dirui Industrial, 2013-2018
  • Revenue and Net Income of Getein Biotech, 2013-2018
  • Revenue Structure of Getein Biotech by Product, 2013-2018
  • Gross Margin of Getein Biotech, 2013-2018
  • IVD Revenue of Getein Biotech, 2013-2018
  • Revenue and Net Income of Guangdong Hybribio Biotech, 2013-2018
  • Revenue Structure of Guangdong Hybribio Biotech by Product, 2013-2018
  • Gross Margin of Guangdong Hybribio Biotech, 2013-2018
  • IVD Revenue of Guangdong Hybribio Biotech, 2013-2018
  • Revenue and Net Income of Beijing Bohui Innovation Biotechnology, 2013-2018
  • Revenue Structure of Beijing Bohui Innovation Biotechnology by Product, 2013-2018
  • Gross Margin of Beijing Bohui Innovation Biotechnology, 2013-2018
  • IVD Revenue of Beijing Bohui Innovation Biotechnology, 2013-2018
  • Revenue and Net Income of Edan Instruments, 2013-2018
  • Revenue Structure of Edan Instruments by Product, 2013-2018
  • Gross Margin of Edan Instruments, 2013-2018
  • IVD Revenue of Edan Instruments, 2013-2018
  • Revenue and Net Income of Wuhan Easy Diagnosis Biomedicine, 2013-2018
  • Revenue Structure of Wuhan Easy Diagnosis Biomedicine by Product, 2013-2018
  • Gross Margin of Wuhan Easy Diagnosis Biomedicine, 2013-2018
  • IVD Revenue of Wuhan Easy Diagnosis Biomedicine, 2013-2018
目次

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China's IVD market has burgeoned due to robust demand over the years, with its size approximating RMB57.6 billion in 2018, an annualized jump of 19.3%.

Reagents now prevail in the Chinese IVD industry, sweeping over 70% of the total value of the industry. In the country, IVD reagents mainly include those for immunological, biochemical and molecular diagnostics, among which the first two kinds of diagnosis reagents are the mainstay of the industry, seizing a combined more than 60% shares.

In China, world-renowned big names such as Roche, Siemens, Abbott and Thermo Fisher are the main players in the high-end IVD market; local companies including Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shanghai Kehua Bio-Engineering Co., Ltd., Maccura Biotechnology Co., Ltd., Autobio Diagnostics Co., Ltd., Dirui Industrial Co., Ltd., Beijing Leadman Biochemistry Co., Ltd., MedicalSystem Biotechnology Co., Ltd. and Sinocare Inc., have gained a firm foothold in the low- and mid-end markets.

China has issued industrial policies to shore up local Chinese IVD companies since 2011, setting the stage for homemade products to replace the imported. Lower price and favorable policies are a boon for Chinese companies to break the monopoly of their foreign peers.

China's IVD industry will head toward the following directions in the years to come:

  • 1. Factors such as population aging, two-child policy and higher health budget will be conducive to the rising demand for IVD;
  • 2. Frequent mergers and acquisitions will make the market more concentrated;
  • 3. High-end immunological diagnostics, molecular diagnostics and point-of-care testing (POCT) will be three major trends.

The report highlights the following:

China IVD industry (development status, market size, market structure, competitive pattern and development trends);

China IVD market segments (development status, competitive pattern and development trends);

China IVD downstream sectors;

6 foreign and 24 Chinese IVD companies (operation, gross margin, IVD business, development strategy, etc.).

Table of Contents

1 Overview

  • 1.1 Definition
  • 1.2 Classification

2 China In Vitro Diagnostic Industry

  • 2.1 Development Status
  • 2.2 Market Size
  • 2.3 Market Structure
  • 2.4 Competitive Pattern
  • 2.5 Development Trends
    • 2.5.1 Aging of Population Spurs IVD Industry
    • 2.5.2 Higher Healthcare Expenditures are a Boon for IVD Industry
    • 2.5.3 Government Backs IVD Industry
    • 2.5.4 High-end Immunological Diagnostics, Molecular Diagnostics and POCT will be Three Major Trends
    • 2.5.5 Related Companies Flock to Capital Market for Further Development
    • 2.5.6 Implementation of Two-child Policy Fuels IVD Industry
    • 2.5.7 Frequent Mergers and Acquisitions are Likely to Make IVD Market More Concentrated

3 China IVD Market Segments

  • 3.1 Companion Diagnostics
    • 3.1.1 Development Status
    • 3.1.2 Market Structure
    • 3.1.3 Market Size
    • 3.1.4 Growth Drivers
    • 3.1.5 Competitive Pattern
  • 3.2 Immunological Diagnostics
    • 3.2.1 Development Status
    • 3.2.2 Competitive Pattern
    • 3.2.3 Development Trends
  • 3.3 Molecular Diagnostics
    • 3.3.1 Development Status
    • 3.3.2 Competitive Pattern
    • 3.3.3 Development Trends
  • 3.4 Biochemical Diagnostics
    • 3.4.1 Development Status
    • 3.4.2 Competitive Pattern
    • 3.4.3 Development Trends
  • 3.5 POCT
    • 3.5.1 Development Status
    • 3.5.2 Competitive Pattern
    • 3.5.3 Development Trends

4 China IVD Downstream Sectors

  • 4.1 Healthcare Sector
    • 4.1.1 Number of Medical Institutions
    • 4.1.2 Medical Services
    • 4.1.3 Medical Income
  • 4.2 Independent Clinical Laboratory Sector
    • 4.2.1 Development Status
    • 4.2.2 Market Size
    • 4.2.3 Competitive Pattern
    • 4.2.4 Development Trends

5 Major Foreign Companies

  • 5.1 Roche
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 In Vitro Diagnostics Business
    • 5.1.4 Development in China
  • 5.2 Siemens
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 In Vitro Diagnostics Business
    • 5.2.4 Development in China
  • 5.3 Abbott
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 In Vitro Diagnostics Business
    • 5.3.4 Development in China
  • 5.4 Thermo Fisher
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 In Vitro Diagnostics Business
    • 5.4.4 Development in China
  • 5.5 Danaher
    • 5.5.1 Profile
    • 5.5.2 Operation
    • 5.5.3 In Vitro Diagnostics Business
    • 5.5.4 Development in China
  • 5.6 Sysmex
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 In Vitro Diagnostics Business
    • 5.6.4 Development in China

6 Major Chinese Companies

  • 6.1 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 6.1.1 Profile
    • 6.1.2 Operation
    • 6.1.3 Gross Margin
    • 6.1.4 In Vitro Diagnostics Business
    • 6.1.5 Development Strategy
  • 6.2 Autobio Diagnostics Co., Ltd.
    • 6.2.1 Profile
    • 6.2.2 Operation
    • 6.2.3 Gross Margin
    • 6.2.4 In Vitro Diagnostics Business
    • 6.2.5 Development Strategy
  • 6.3 Beijing Strong Biotechnologies, Inc.
    • 6.3.1 Profile
    • 6.3.2 Operation
    • 6.3.3 Gross Margin
    • 6.3.4 In Vitro Diagnostics Business
    • 6.3.5 Development Strategy
  • 6.4 MedicalSystem Biotechnology Co., Ltd.
    • 6.4.1 Profile
    • 6.4.2 Operation
    • 6.4.3 Gross Margin
    • 6.4.4 In Vitro Diagnostics Business
    • 6.4.5 Development Strategy
  • 6.5 DAAN Gene Co., Ltd. of Sun Yat-sen University
    • 6.5.1 Profile
    • 6.5.2 Operation
    • 6.5.3 Gross Margin
    • 6.5.4 In Vitro Diagnostics Business
    • 6.5.5 Development Strategy
  • 6.6 Beijing Leadman Biochemistry Co., Ltd.
    • 6.6.1 Profile
    • 6.6.2 Operation
    • 6.6.3 Gross Margin
    • 6.6.4 In Vitro Diagnostics Business
    • 6.6.5 Development Strategy
  • 6.7 Sinocare Inc.
    • 6.7.1 Profile
    • 6.7.2 Operation
    • 6.7.3 Gross Margin
    • 6.7.4 In Vitro Diagnostics Business
    • 6.7.5 Development Strategy
  • 6.8 Shanghai Kehua Bio-Engineering Co., Ltd.
    • 6.8.1 Profile
    • 6.8.2 Operation
    • 6.8.3 Gross Margin
    • 6.8.4 In Vitro Diagnostics Business
    • 6.8.5 Development Strategy
  • 6.9 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • 6.9.1 Profile
    • 6.9.2 Operation
    • 6.9.3 Gross Margin
    • 6.9.4 In Vitro Diagnostics Business
    • 6.9.5 Development Strategy
  • 6.10 Livzon Pharmaceutical Group Inc.
    • 6.10.1 Profile
    • 6.10.2 Operation
    • 6.10.3 Gross Margin
    • 6.10.4 In Vitro Diagnostics Business
    • 6.10.5 Development Strategy
  • 6.11 Maccura Biotechnology Co., Ltd.
    • 6.11.1 Profile
    • 6.11.2 Operation
    • 6.11.3 Gross Margin
    • 6.11.4 In Vitro Diagnostics Business
    • 6.11.5 Development Strategy
  • 6.12 Guangzhou Wondfo Biotech Co., Ltd.
    • 6.12.1 Profile
    • 6.12.2 Operation
    • 6.12.3 Gross Margin
    • 6.12.4 In Vitro Diagnostics Business
    • 6.12.5 Development Strategy
  • 6.13 Biosino Bio-Technology and Science Inc.
    • 6.13.1 Profile
    • 6.13.2 Operation
    • 6.13.3 Gross Margin
    • 6.13.4 In Vitro Diagnostics Business
    • 6.13.5 Development Strategy
  • 6.14 Jiangsu Bioperfectus Technologies Co., Ltd.
    • 6.14.1 Profile
    • 6.14.2 Operation
    • 6.14.3 Gross Margin
    • 6.14.4 In Vitro Diagnostics Business
    • 6.14.5 Development Strategy
  • 6.15 Zhejiang Orient Gene Biotech Co., Ltd.
    • 6.15.1 Profile
    • 6.15.2 Operation
    • 6.15.3 Gross Margin
    • 6.15.4 In Vitro Diagnostics Business
    • 6.15.5 Development Strategy
  • 6.16 HOB Biotech Group Suzhou Co., Ltd.
    • 6.16.1 Profile
    • 6.16.2 Operation
    • 6.16.3 Gross Margin
    • 6.16.4 In Vitro Diagnostics Business
    • 6.16.5 Development Strategy
  • 6.17 Lifotronic Technology Co., Ltd.
    • 6.17.1 Profile
    • 6.17.2 Operation
    • 6.17.3 Gross Margin
    • 6.17.4 In Vitro Diagnostics Business
    • 6.17.5 Development Strategy
  • 6.18 Hotgen Biotech Co., Ltd.
    • 6.18.1 Profile
    • 6.18.2 Operation
    • 6.18.3 Gross Margin
    • 6.18.4 In Vitro Diagnostics Business
    • 6.18.5 Development Strategy
  • 6.19 Dirui Industrial Co., Ltd.
    • 6.19.1 Profile
    • 6.19.2 Operation
    • 6.19.3 Gross Margin
    • 6.19.4 In Vitro Diagnostics Business
    • 6.19.5 Development Strategy
  • 6.20 Getein Biotech, Inc.
    • 6.20.1 Profile
    • 6.20.2 Operation
    • 6.20.3 Gross Margin
    • 6.20.4 In Vitro Diagnostics Business
    • 6.20.5 Development Strategy
  • 6.21 Guangdong Hybribio Biotech Co., Ltd.
    • 6.21.1 Profile
    • 6.21.2 Operation
    • 6.21.3 Gross Margin
    • 6.21.4 In Vitro Diagnostics Business
    • 6.21.5 Development Strategy
  • 6.22 Beijing Bohui Innovation Biotechnology Co., Ltd.
    • 6.22.1 Profile
    • 6.22.2 Operation
    • 6.22.3 Gross Margin
    • 6.22.4 In Vitro Diagnostics Business
    • 6.22.5 Development Strategy
  • 6.23 Edan Instruments, Inc.
    • 6.23.1 Profile
    • 6.23.2 Operation
    • 6.23.3 Gross Margin
    • 6.23.4 In Vitro Diagnostics Business
    • 6.23.5 Development Strategy
  • 6.24 Wuhan Easy Diagnosis Biomedicine Co., Ltd.
    • 6.24.1 Profile
    • 6.24.2 Operation
    • 6.24.3 Gross Margin
    • 6.24.4 In Vitro Diagnostics Business
    • 6.24.5 Development Strategy
Back to Top